# OnCo record nct06405490 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06405490/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06405490", "NCT06405490" ;
  schema:name "NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC"@en ;
  schema:description "A phase 2 trial of cAPOX (capecitabine, oxaliplatin), capecitabine and cadonilimab in pancreatic cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06405490/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06405490> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest", "pancreatic-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/locally-advanced-pdac/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/cadonilimab/> .